InMode (NASDAQ:INMD) Stock Price Crosses Above Two Hundred Day Moving Average – Should You Sell?

Posted by Brian Himes on Sep 3rd, 2026

InMode Ltd. (NASDAQ:INMD – Get Free Report) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $14.26 and traded as high as $15.20. InMode shares last traded at $15.03, with a volume of 799,933 shares trading hands.

Analysts Set New Price Targets

Several brokerages have recently issued reports on INMD. Robert W. Baird reduced their price objective on InMode from $17.00 to $14.00 and set a “neutral” rating for the company in a research report on Thursday, May 7th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of InMode in a research note on Thursday, August 6th. Finally, Barclays set a $19.00 target price on InMode and gave the company an “overweight” rating in a research note on Thursday, May 7th. One analyst has rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $16.00.

Get Our Latest Stock Analysis on InMode

InMode Stock Down 0.7%

The stock has a market cap of $853.02 million, a price-to-earnings ratio of 12.07 and a beta of 1.86. The company’s 50-day simple moving average is $15.06 and its 200-day simple moving average is $14.27.

InMode (NASDAQ:INMD – Get Free Report) last announced its earnings results on Wednesday, August 5th. The healthcare company reported $0.35 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.35. InMode had a return on equity of 11.99% and a net margin of 20.69%.The company had revenue of $95.59 million for the quarter, compared to analyst estimates of $94.89 million. During the same period in the previous year, the firm earned $0.47 earnings per share. InMode’s revenue for the quarter was up .0% compared to the same quarter last year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Leonteq Securities AG acquired a new position in InMode in the 4th quarter valued at approximately $26,000. Quadrant Capital Group LLC lifted its stake in shares of InMode by 127.8% in the fourth quarter. Quadrant Capital Group LLC now owns 1,945 shares of the healthcare company’s stock worth $29,000 after buying an additional 1,091 shares during the last quarter. Advisory Services Network LLC acquired a new position in InMode during the 3rd quarter worth $37,000. Basepoint Wealth LLC bought a new stake in InMode during the 4th quarter valued at approximately $39,000. Finally, Deutsche Bank AG boosted its position in shares of InMode by 35.9% in the fourth quarter. Deutsche Bank AG now owns 3,927 shares of the healthcare company’s stock valued at $58,000 after acquiring an additional 1,037 shares during the period. 68.04% of the stock is currently owned by institutional investors and hedge funds.

InMode Company Profile

(Get Free Report)

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.